Have a feature idea you'd love to see implemented?
Let us know!
CYTK Cytokinetics Inc
Price (delayed)
$54.4
Market cap
$6.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.37
Enterprise value
$7B
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by
Highlights
CYTK's equity has surged by 133% year-on-year and by 127% since the previous quarter
Cytokinetics's quick ratio has increased by 47% from the previous quarter and by 19% YoY
The revenue has dropped by 69% year-on-year and by 16% since the previous quarter
Cytokinetics's gross profit has plunged by 69% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of CYTK
Market
Valuations
Earnings
Shares outstanding
117.66M
Market cap
$6.4B
Enterprise value
$7B
Price to earnings (P/E)
N/A
Price to book (P/B)
52.55
Price to sales (P/S)
1,896.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,233.8
Revenue
$3.13M
EBIT
-$511.14M
EBITDA
-$498.22M
Free cash flow
-$401.27M
Per share
Balance sheet
Liquidity
EPS
-$5.37
Free cash flow per share
-$3.67
Book value per share
$1.04
Revenue per share
$0.03
TBVPS
$13.95
Total assets
$1.52B
Total liabilities
$1.42B
Debt
$790.18M
Equity
$108.55M
Working capital
$965.03M
Debt to equity
7.28
Current ratio
10.39
Quick ratio
10.28
Net debt/EBITDA
-1.2
Margins
Efficiency
Dividend
EBITDA margin
-15,897.2%
Gross margin
100%
Net margin
-17,398.8%
Operating margin
-16,148.4%
Return on assets
-56%
Return on equity
N/A
Return on invested capital
-33.8%
Return on capital employed
-36%
Return on sales
-16,309.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYTK stock price
How has the Cytokinetics stock price performed over time
Intraday
0.13%
1 week
3.4%
1 month
-2.56%
1 year
71.61%
YTD
-34.84%
QTD
3.03%
Financial performance
How have Cytokinetics's revenue and profit performed over time
Revenue
$3.13M
Gross profit
$3.13M
Operating income
-$506.09M
Net income
-$545.28M
Gross margin
100%
Net margin
-17,398.8%
The revenue has dropped by 69% year-on-year and by 16% since the previous quarter
Cytokinetics's gross profit has plunged by 69% YoY and by 16% from the previous quarter
The net margin has decreased by 23% from the previous quarter
Cytokinetics's operating margin has decreased by 22% from the previous quarter
Growth
What is Cytokinetics's growth rate over time
Valuation
What is Cytokinetics stock price valuation
P/E
N/A
P/B
52.55
P/S
1,896.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,233.8
The EPS has grown by 6% YoY
CYTK's equity has surged by 133% year-on-year and by 127% since the previous quarter
The revenue has dropped by 69% year-on-year and by 16% since the previous quarter
CYTK's P/S is 45% above its last 4 quarters average of 1306.4
Efficiency
How efficient is Cytokinetics business performance
The ROS has contracted by 22% from the previous quarter
The company's return on assets rose by 17% QoQ and by 2.4% YoY
CYTK's return on invested capital is up by 9% since the previous quarter
Dividends
What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYTK.
Financial health
How did Cytokinetics financials performed over time
The total assets is 8% greater than the total liabilities
The total assets has surged by 95% year-on-year and by 89% since the previous quarter
Cytokinetics's quick ratio has increased by 47% from the previous quarter and by 19% YoY
CYTK's equity has surged by 133% year-on-year and by 127% since the previous quarter
The debt has increased by 5% YoY and by 4.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.